CDX Stock Overview
Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CardieX Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.062 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.045 |
| Beta | 1.41 |
| 1 Month Change | -36.73% |
| 3 Month Change | -40.95% |
| 1 Year Change | -16.22% |
| 3 Year Change | -84.30% |
| 5 Year Change | -63.53% |
| Change since IPO | -99.11% |
Recent News & Updates
Shareholder Returns
| CDX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -7.5% | -3.0% | 0.08% |
| 1Y | -16.2% | -17.1% | -3.9% |
Return vs Industry: CDX matched the Australian Medical Equipment industry which returned -17.1% over the past year.
Return vs Market: CDX underperformed the Australian Market which returned -3.9% over the past year.
Price Volatility
| CDX volatility | |
|---|---|
| CDX Average Weekly Movement | 19.5% |
| Medical Equipment Industry Average Movement | 11.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 16.3% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: CDX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: CDX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Craig Cooper | cardiex.com |
CardieX Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring.
CardieX Limited Fundamentals Summary
| CDX fundamental statistics | |
|---|---|
| Market cap | AU$25.12m |
| Earnings (TTM) | -AU$14.55m |
| Revenue (TTM) | AU$5.72m |
4.4x
P/S Ratio-1.7x
P/E RatioIs CDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDX income statement (TTM) | |
|---|---|
| Revenue | AU$5.72m |
| Cost of Revenue | AU$837.46k |
| Gross Profit | AU$4.89m |
| Other Expenses | AU$19.43m |
| Earnings | -AU$14.55m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | 85.37% |
| Net Profit Margin | -254.16% |
| Debt/Equity Ratio | 69.2% |
How did CDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 23:53 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CardieX Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Kallos | MST Financial Services Pty Limited |